Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Bids For AnorMED Eyeing Stem Cell Transplantation Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

Genzyme appeals directly to shareholders after rejection from AnorMed’s board of directors.

You may also be interested in...



Genzyme Wins AnorMED As Millennium Backs Out Of Bidding War

Genzyme gains late-stage product candidate Mozobil for approximately $580 mil.

Genzyme Wins AnorMED As Millennium Backs Out Of Bidding War

Genzyme gains late-stage product candidate Mozobil for approximately $580 mil.

Genzyme Raises Bid For AnorMED, Emphasizing Market Advantage For Mozobil

Latest bid is 12.5% higher than Millennium’s, but the firm will have three days to match it if needed.

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel